Observational studyDrug design, development and therapy2025
Effects of Different Body Mass Indexes on the Induction Dose of Remimazolam in Patients Undergoing Gynaecological Day Surgery: A Propensity Score-Matched Study.
Observational study in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal Dosing Strategies for Remimazolam Across Diverse Patient Populations: A Clinical Narrative Review.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study compared the effects of different body mass indexes (BMI) on the induction dose of remimazolam in patients undergoing gynaecological day surgery, aiming to explore the appropriate weight index of remimazolam for overweight or obese people. Patients and Methods: This was a retrospective, observational study based on propensity score matching (PSM). The patients were divided into two groups according to normal BMI boundaries: group N (BMI<24 kg/m²) and group F (BMI≥24 kg/m²). The primary observation of the study was the anesthetic induction dose per kg of remimazolam calculated on the basis of total body weight (TBW), ideal body weight (IBW), lean body weight (LBW) and corrected body weight (CBW). Results: A total of 250 patients were included in the analysis. After PSM, 94 patients were finally included in each group. The primary observation: there was a significant difference between the two groups in the induction dose per kg of TBW and IBW ( Conclusion: When calculated based on TBW, the induction dose of remimazolam per kilogram (mg/kg) was lower in overweight or obese patients compared to normal-weight patients. For these patients, we recommend using CBW for dose calculation when applying the 0.2-0.4 mg/kg dosing regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.